These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 28587532)

  • 1. Novel tetrazole and cyanamide derivatives as inhibitors of cyclooxygenase-2 enzyme: design, synthesis, anti-inflammatory evaluation, ulcerogenic liability and docking study.
    Lamie PF; Philoppes JN; Azouz AA; Safwat NM
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):805-820. PubMed ID: 28587532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel tetrazole-based selective COX-2 inhibitors: Design, synthesis, anti-inflammatory activity, evaluation of PGE
    Labib MB; Fayez AM; El-Nahass ES; Awadallah M; Halim PA
    Bioorg Chem; 2020 Nov; 104():104308. PubMed ID: 33011534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents.
    Ahmed EM; Kassab AE; El-Malah AA; Hassan MSA
    Eur J Med Chem; 2019 Jun; 171():25-37. PubMed ID: 30904755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective cyclooxygenase inhibition and ulcerogenic liability of some newly prepared anti-inflammatory agents having thiazolo[4,5-d]pyrimidine scaffold.
    Bakr RB; Ghoneim AA; Azouz AA
    Bioorg Chem; 2019 Jul; 88():102964. PubMed ID: 31075742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, analgesic, anti-inflammatory activity of novel pyrazolones possessing aminosulfonyl pharmacophore as inhibitors of COX-2/5-LOX enzymes: Histopathological and docking studies.
    Abdelgawad MA; Labib MB; Ali WAM; Kamel G; Azouz AA; El-Nahass ES
    Bioorg Chem; 2018 Aug; 78():103-114. PubMed ID: 29550530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New pyridazine derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents; design, synthesis and biological evaluation.
    Ahmed EM; Hassan MSA; El-Malah AA; Kassab AE
    Bioorg Chem; 2020 Jan; 95():103497. PubMed ID: 31838289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-acidic 1,3,4-trisubstituted-pyrazole derivatives as lonazolac analogs with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile.
    Abdellatif KRA; Fadaly WAA; Elshaier YAMM; Ali WAM; Kamel GM
    Bioorg Chem; 2018 Apr; 77():568-578. PubMed ID: 29475165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide release studies.
    Fadaly WAA; Elshaier YAMM; Hassanein EHM; Abdellatif KRA
    Bioorg Chem; 2020 May; 98():103752. PubMed ID: 32197148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1,5-diarylpyrazole derivatives.
    Abdellatif KR; Fadaly WA; Ali WA; Kamel GM
    J Enzyme Inhib Med Chem; 2016; 31(sup3):54-60. PubMed ID: 27541738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of pyrazole-based compounds with 1,2,4-triazole-3-thiol moiety as selective COX-2 inhibitors cardioprotective drug candidates: Design, synthesis, cyclooxygenase inhibition, anti-inflammatory, ulcerogenicity, cardiovascular evaluation, and molecular modeling studies.
    Abdellatif KRA; Abdelall EKA; Elshemy HAH; Philoppes JN; Hassanein EHM; Kahk NM
    Bioorg Chem; 2021 Sep; 114():105122. PubMed ID: 34243075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and anti-inflammatory assessment of certain substituted 1,2,4-triazoles bearing tetrahydroisoquinoline scaffold as COX 1/2-inhibitors.
    Abo-Elmagd MI; Hassan RM; Aboutabl ME; Amin KM; El-Azzouny AA; Aboul-Enein MN
    Bioorg Chem; 2024 Sep; 150():107577. PubMed ID: 38941697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of pyrimidine-5-carbonitrile hybrids as COX-2 inhibitors: Anti-inflammatory activity, ulcerogenic liability, histopathological and docking studies.
    Alfayomy AM; Abdel-Aziz SA; Marzouk AA; Shaykoon MSA; Narumi A; Konno H; Abou-Seri SM; Ragab FAF
    Bioorg Chem; 2021 Mar; 108():104555. PubMed ID: 33376011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,4-Dihydroquinazolin-3(2H)-yl benzamide derivatives as anti-inflammatory and analgesic agents with an improved gastric profile: Design, synthesis, COX-1/2 inhibitory activity and molecular docking study.
    Sakr A; Kothayer H; Ibrahim SM; Baraka MM; Rezq S
    Bioorg Chem; 2019 Mar; 84():76-86. PubMed ID: 30481648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, evaluation and molecular modelling studies of some novel 5,6-diphenyl-1,2,4-triazin-3(2H)-ones bearing five-member heterocyclic moieties as potential COX-2 inhibitors: A hybrid pharmacophore approach.
    Banerjee AG; Das N; Shengule SA; Sharma PA; Srivastava RS; Shrivastava SK
    Bioorg Chem; 2016 Dec; 69():102-120. PubMed ID: 27750057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New indomethacin analogs as selective COX-2 inhibitors: Synthesis, COX-1/2 inhibitory activity, anti-inflammatory, ulcerogenicity, histopathological, and docking studies.
    Abdellatif KRA; Abdelall EKA; Elshemy HAH; El-Nahass ES; Abdel-Fattah MM; Abdelgawad YYM
    Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000328. PubMed ID: 33314237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of phenylpiperazine derivatives of 1,4-benzodioxan as selective COX-2 inhibitors and anti-inflammatory agents.
    Sun J; Wang S; Sheng GH; Lian ZM; Liu HY; Zhu HL
    Bioorg Med Chem; 2016 Nov; 24(21):5626-5632. PubMed ID: 27658794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 1,3-diaryl pyrazole derivatives bearing methylsulfonyl moiety: Design, synthesis, molecular docking and dynamics, with dual activities as anti-inflammatory and anticancer agents through selectively targeting COX-2.
    Shaker AMM; Shahin MI; AboulMagd AM; Abdel Aleem SA; Abdel-Rahman HM; Abou El Ella DA
    Bioorg Chem; 2022 Dec; 129():106143. PubMed ID: 36191430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of Hydroxybenzofuranyl-pyrazolyl and Hydroxyphenyl-pyrazolyl Chalcones and Their Corresponding Pyrazoline Derivatives as COX Inhibitors, Anti-inflammatory and Gastroprotective Agents.
    Ragab FAE; Mohammed EI; Abdel Jaleel GA; Selim AAMAE; Nissan YM
    Chem Pharm Bull (Tokyo); 2020; 68(8):742-752. PubMed ID: 32741915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, modeling studies and biological evaluation of thiazolidine derivatives containing pyrazole core as potential anti-diabetic PPAR-γ agonists and anti-inflammatory COX-2 selective inhibitors.
    Abdellatif KRA; Fadaly WAA; Kamel GM; Elshaier YAMM; El-Magd MA
    Bioorg Chem; 2019 Feb; 82():86-99. PubMed ID: 30278282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and pharmacological evaluation of novel and selective COX-2 inhibitors based on celecoxib scaffold supported with in vivo anti-inflammatory activity, ulcerogenic liability, ADME profiling and docking study.
    Abdellatif KRA; Abdelall EKA; Elshemy HAH; Philoppes JN; Hassanein EHM; Kahk NM
    Bioorg Chem; 2022 Mar; 120():105627. PubMed ID: 35065465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.